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The renin-angiotensin system (RAS) plays a pathophysiologic
role in the progression of chronic renal disease. Inhibition of
angiotensin II (Ang II) in experimental and human renal dis-
eases decreases proteinuria, reduces histologic evidence of
renal injury, and slows progression to end-stage renal failure.
However, available measurements of components of the RAS
in most experimental models and clinical types of chronic renal
disease do not suggest extraordinary systemic activation of this
system. In this article we will examine this apparent paradox
and offer several explanations for why this paradox might exist.
Role of the renin-angiotensin system in progressive renal
disease
Evidence supporting a role for the RAS in the progression of
renal disease derives primarily from studies of Ang II inhibition.
The remnant kidney model of chronic renal disease is charac-
terized by increased filtration in residual nephrons due to
increased glomerular plasma flow and capillary hydraulic pres-
sure [1]. These presumably compensatory mechanisms for
maintenance of single nephron GFR are thought to be injurious
in the long term. Anderson et al found that control of glomerular
and systemic hypertension with ACE inhibitor therapy reduced
renal injury as measured by lesser glomerular histologic damage
and proteinuria [2]. Subsequently, this group demonstrated a
pivotal role for glomerular hypertension in mediating glomeru-
lar injury, as equal reduction of systemic blood pressure with a
combination of antihypertensive agents failed to achieve equal
correction of glomerular hypertension compared to chronic
ACE inhibition [3]. ACE inhibition was associated with alter-
ations in renal vascular tone and the glomerular ultrafiltration
coefficient. Specifically, renal vascular resistance fell but to a
greater extent in the efferent than in the afferent segments.
Since Ang II exerts greater vasoconstriction on the efferent
than afferent arteriole, the actions of ACE inhibition on renal
resistance vessels imply that there is a tonic action of Ang II in
the remnant kidney [4, 5]. Also, the ultrafiltration coefficient
rose with ACE inhibition, another phenomenon consistent with
relief from Ang II action. Similar directional changes in glomer-
ular hemodynamics and proteinuria with acute Ang II inhibition
(ACE inhibitor and Ang II receptor antagonism) in the remnant
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model have been reported by Pelayo, Quan and Shanley [6].
Taken together these studies suggest elevated intrarenal Ang II
actions contribute to the cascade of injurious events leading to
proteinuria and glomerular sclerosis.
Meyer et al have examined the effects of RAS interruption in
established renal injury, a scenario more closely reflecting the
therapy of clinical renal disease [7]. Enalapril treatment initi-
ated eight weeks following subtotal nephrectomy in the rat, a
point at which substantial proteinuria, hypertension and gb-
merular injury are present, not only reversed the existing
glomerular and systemic hypertension but also provided pro-
tection against further glomerular injury. Again, the pattern of
changes in glomerular hemodynamics was consistent with re-
moval of Ang II's actions. Urinary protein excretion rates were
stabilized and indices of glomerular sclerosis were markedly
improved by introduction of both ACE inhibition and dietary
protein restriction, a modulator of the RAS (see below). Thus,
RAS interruption imposed upon ongoing gbomerular disease
alters renal hemodynamics in a pattern consistent with abroga-
tion of Ang II action and imparts protection from progressive
glomerular sclerosis.
Experimental and clinical diabetic glomerulopathy is charac-
terized by marked microcirculatory and structural alterations
[8, 9]. Early in this condition, as in the remnant model,
hyperperfusion and glomertilar hypertension contribute to hy-
perfiltration although systemic hypertension is not coincident
[101. ACE inhibition in persistently hyperglycemic animals
reduces glomerular hypertension without reversing hyperfiltra-
tion early in the course of experimental diabetes and subse-
quently prevents the expression of chronic glomerular injury,
suggesting renal hemodynamic perturbations as pathophysio-
logic features of diabetes and that the RAS may be contributing
to these perturbations [9]. Differential renal effects of antihy-
pertensive therapy have also been noted in experimental diabe-
tes [10]. As in the remnant model, ACE inhibition was advan-
tageous compared to a combination of other antihypertensives,
findings that further support a role for the RAS in the evolution
of this disease model.
Puromycin aminonucleoside induced nephrotic syndrome is a
model of glomerular injury, proteinuria and progressive glomer-
ular sclerosis with a triphasic pattern of initial nephrotic syn-
drome with impaired GFR, subsequent spontaneous resolution
of proteinuria, and eventual recurrent proteinuria with marked
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glomerular sclerosis. Pretreatment with enalapril failed to re-
duce the proteinuria or fall in GFR of the initial phase, despite
small reductions in systemic blood pressure [11]. However,
enalapril effectively reduced systemic and glomerular hyperten-
sion during the intermediate phase (8 to 10 weeks) a time
characterized by spontaneous resolution of proteinuria. During
the chronic phase (24 to 70 weeks), ACE inhibitor treatment
resulted in marked attenuation of proteinuria, glomerular scle-
rosis and tubulointerstitial injury and was associated with
preservation of glomerular filtration rate [11]. Although the
effects of systemic blood pressure reduction by other means
have not been tested, this study reinforces the finding in other
models and provides further evidence for Ang II actions mod-
ulating progression of chronic renal disease. In addition, Dia-
mond and Anderson established a correlation between the
magnitude of proteinuria and the severity of tubulointerstitial
damage, suggesting that ACE inhibition may attenuate this
common accompanying feature of many progressive renal dis-
eases [12]. Although speculative, it can be envisioned that
decreased Ang II action in the glomerulus with subsequent
reduction in filtered protein load to the tubular compartment
may translate into decreased tubular injury. Further evidence
derived largely from use of ACE inhibitors exists in various
disease models (for example Heymann nephntis, SHR-unine-
phrectomy) to support the general tenet that the RAS partici-
pates in many if not all forms of chronic experimental renal
injury [13—16].
Control of hypertension in patients with chronic renal dis-
ease, reduces the rate of decay in renal function [17]. Although
a variety of antihypertensive agents seem to have this beneficial
effect, ACE inhibitors may have a more specific effect on
reducing renal injury, although definitive clinical evidence
supporting such a differential effect is currently lacking. ACE
inhibitors have been reported to influence favorably the course
of a variety of human renal diseases including primary glomer-
ulopathies, diabetes mellitus, systemic lupus erythematosus,
hypertensive renal disease, polycystic kidney disease, chronic
pyelonephntis and sickle cell nephropathy [16, 18—37]. In most
cases, converting enzyme inhibition was associated with a
reduction in proteinuria, and in some cases with a slowing in the
rate of progression of renal disease. However, most of these
studies did not examine an optimal control population to
differentiate the effects of blood pressure reduction from a more
specffic effect of ACE inhibitors on renal function. Several
studies have attempted to more directly compare converting
enzyme inhibitors and other agents. Ruilope et al contrasted the
rate of progression of renal disease in 10 patients treated for 12
months with the ACE inhibitor captopril to their previous rate
of progression while they were receiving an antihypertensive
regimen consisting of propranolol, hydralazine, and furosemide
[29]. These investigators demonstrated a decrease in the rate of
progression of the renal disease with converting enzyme inhi-
bition. The retrospective use of the patients' previous rate of
progression weakens the interpretation of this study as uniden-
tilled "time" effects may slow progression [33]. Heeg and
colleagues also compared the antiproteinuric effects of the
converting enzyme inhibitor lisinopnl to prior therapy with
methyldopa and other conventional agents, and demonstrated a
more consistent reduction in proteinuria after ACE inhibition
[26, 27].
In patients with essential hypertension, converting enzyme
inhibitor therapy with captopnl reduced microalbuminuria,
whereas no change in albumin excretion occurred in a separate
group of patients treated with beta-blockers and diuretics [31].
Comparisons of different agents in normotensive diabetic pa-
tients with microalbuminuna have yielded somewhat conflicting
results, with some studies demonstrating a beneficial effect of
converting enzyme inhibitors over other agents while other
studies have not demonstrated such a differential effect [23, 24].
The issue is further clouded by the demonstration of a signifi-
cant slowing of the progression of diabetic kidney disease by
regimens without converting enzyme inhibitors and by the
ability of these regimens to reduce proteinuria [38, 39]. There-
fore, the important clinical issue of whether there are differen-
tial effects of antihypertensives on renal injury is yet unan-
swered in its definitive form.
Recent studies have begun to address the critical issue of
long-term renal protective effects of ACE inhibition versus
other therapy. Treatment with the ACE inhibitor enalapril for
an average of 2.2 years resulted in a slower rate of decline of
GFR compared to comparable blood pressure reduction with
metoprolol in patients with established diabetic nephropathy
[35]. In contrast, no differential renal protective effect between
captopril and nifedipine was demonstrated in non-diabetic
chronic renal failure patients followed for three years [36].
These patients were also being treated with dietary protein
restriction which may have accounted for the lack of any
difference between these agents.
Metabolism of the renin-angiotensin system in chronic renal
disease
Renin is classically regarded as the rate limiting step in the
formation of Ang II, but other components of the renin-
angiotensin cascade may influence Ang II generation. The
assessment of Ang II effect is further complicated by the fact
that end-organ response reflects the cumulative action of ambi-
ent angiotensins (subtype, concentration), Ang II receptors
(affinity, receptor number and type), as well as tissue respon-
siveness (comodulators, second messengers). Thus, the stron-
gest evidence for a role of the RAS in chronic renal disease is
not steady-state level of a particular component, even a critical
one such as renin or Ang II, but rather the demonstration of an
effect of blockade of the system. Nevertheless, a review of
levels and activities of the components of the RAS in the setting
of chronic renal disease does have some utility in defining the
role of this system in chronic renal disease and in discerning the
points at which its control is altered.
Renin, synthesized principally in the juxtaglomerular appara-
tus, is an aspartyl proteinase with marked substrate specificity
limited to one region of the angiotensinogen peptide. The
synthesis and secretion of renin are generally considered key
regulated steps in Ang II generation. The constitutive release of
the inactive prorenin and the regulated secretion of active renin
result in a circulating total renin composed principally of the
inactive prorenin form [40]. Conflicting evidence exists for the
capacity of circulating prorenin to undergo conversion to active
renin. However, no clear physiological or pathologic role for
circulating prorenin has yet been elucidated.
Chronic renal disease is usually marked by low to normal
PRA despite functional evidence suggesting that the RAS exerts
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hemodynamic actions in this condition. In the remnant kidney
model, the available measurements of circulating levels of renin
concentration and Ang II do not suggest extraordinary systemic
activation of this system [3, 41—43]. Ylitalo et al demonstrated
lower PRA, Ang II concentration, and renal renin content in
subtotally nephrectomized (induced by uninephrectomy com-
bined with upper and lower polectomy of the contralateral
kidney) compared to control rats [42, 43]. The RAS in the rats
with reduced renal mass was still influenced by changes in
sodium intake [42]. Indeed, during high sodium intake, PRA
was suppressed to a greater degree in these animals compared
to a sham operated group. Following subtotal nephrectomy
(induced by uninephrectomy and infarction of 2/3 of the con-
tralateral kidney) plasma levels of total renin, active renin and
hence their difference, inactive renin, are similar to those in
sham operated rats [3, 41].
In the setting of chronic renal disease, limited information is
available regarding systemic Ang II levels. As mentioned
above, Ylitalo et al documented decreased plasma Ang II
concentration following 70% nephrectomy in rats [42]. Sys-
temic Ang II levels, however, likely do not reflect local Ang II
concentrations in the kidney. Evidences for local renal synthe-
sis of Ang II include the presence in the kidney of all the
components necessary for Ang II generation, higher renal
venous and lymphatic levels of Ang II than predicted based on
the renal degradative rates of arterial Ang II, and measurable
levels of renal tissue Ang II which are regulated by modulation
of dietary sodium or ACE inhibition [44—46]. Furthermore,
Seikaly, Arant and Seney quantitated Ang II concentrations in
specific intrarenal fluid compartments and demonstrated very
high levels of Ang II in glomerular filtrate, star vessel plasma,
and the lumen of the proximal tubule compared to systemic
levels, again suggesting intrarenal formation of Ang II [47].
Indirect evidence, in at least some renal diseases, that
glomerular Ang II concentration may be higher than suggested
by measurement of systemic levels of components of the RAS
derives from studies examining Ang II receptor density. Ball-
erman, Skorecki and Brenner demonstrated significantly lower
glomerular Ang II receptor number despite lower plasma renin
concentration in untreated diabetic rats compared to non-
diabetic controls [48]. Based on the well-described reciprocal
relationship between Ang II concentration and receptor den-
sity, one would suspect that glomerular levels of Ang II were
elevated in these diabetic rats resulting in a down-regulation of
local receptor number. Wilkes confirmed this finding and dem-
onstrated a progressive recovery of glomerular angiotensin
receptor density over 60 days from the induction of diabetes
[49]. These changes in the number of Ang II receptors occurred
despite the lack of a difference in PRA or systemic Ang II
between diabetic and control rats.
Employing a nephrotoxic serum nephritis model, Timmer-
mans et al demonstrated an evolving course of dissociation of
Ang II and glomerular receptor density [13]. Initial down-
regulation of receptor number in response to high ambient Ang
II levels early in the course of this disease gave way to a
disordered receptor/ligand relationship. As the disease per-
sisted, renal Ang II levels decreased and remained low, yet Ang
II receptor number increased and remained elevated compared
to control rats. Enalapril, which further reduced Ang II levels,
failed to up-regulate glomerular receptor density but offered
significant reduction in proteinuria. Thus, interruption of the
RAS afforded protection against glomerular injury perhaps by
resetting a disordered receptor-ligand relationship. Hale et al
quantitated glomerular Ang II receptors in patients with IgA
nephropathy and noted no difference in receptor number in
patients compared to controls [50]. These investigators were
unable to demonstrate a correlation between Ang II receptor
density and histologic changes. With the cloning of the Ang II
receptor more detailed studies of its control in the setting of
chronic renal disease should now become possible [51, 52].
ACE is a transmembrane glycoprotein peptidase capable of
cleaving Ang II from Ang I. This enzyme exists in a free
circulating form whose physiologic regulation and function is
poorly understood. With ACE inhibitor therapy a dissociation
between changes in circulating and tissue ACE activity is seen
which may account for some of the sustained effects of ACE
inhibition even when systemic activity has returned to normal
[53]. Intrarenal ACE is present in both endothelial and epithelial
cells. The pars recta of the proximal tubule appears to express
the greatest quantity of ACE largely in the luminal brush
border, but ACE is also present in the basolateral membrane.
Although the human glomerulus is strikingly devoid of ACE,
glomerular ACE has been demonstrated in various animal
models [54].
The largest body of literature regarding ACE involves the use
of ACE inhibitors and is reviewed above. Limited information
exists for the functional action of circulating ACE in chronic
renal disease. ACE activity is increased in puromycin amino-
nucleoside nephrosis [55], and Patel and Ansari demonstrated
increased plasma ACE activity in approximately 60% of chronic
hemodialysis patients [56]. The functional significance of these
increases in ACE activity remain to be determined.
Angiotensinogase A (ATA) is a tissue bound proteinase
involved in the intrarenal degradation of active Ang II. ATA is
primarily expressed in glomerular endothelial, epithelial and
juxtaglomerular cells. Wolf, Thaiss and Scherberich have dem-
onstrated enhanced ATA activity in the glomeruli of rats five
weeks after subtotal nephrectomy [57]. Enalapril inhibited this
enhanced ATA activity presumably through reduction in gb-
merular Ang II concentration. Of note, furosemide therapy with
attendant increased PRA induced parallel increases in ATA
activity. Although the increase of ATA after subtotal nephrec-
tomy wains at 14 weeks, it is postulated that a direct substrate
(Ang II) induction of this degradative system is at play in the
remnant kidney.
Paradox
Although changes in some components of the RAS may
occur, activation of the RAS is not a prominent feature of
chronic renal disease. Yet the response to Ang II inhibition
suggests a pathophysiobogic role for the RAS in the progression
of renal disease. Several possibilities for this apparent paradox
are discussed below.
Renin is inappropriately elevated for the degree of renal
failure
The similarity of plasma renin levels in the setting of reduced
nephron number suggests that the secretory rates for active
renin and prorenin may be increased for remnant nephrons.
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This inference depends on several reasonable assumptions. The
metabolic clearance rate for renin falls by about one half with
complete nephrectomy [58]. However, the renal function (GFR)
with subtotal nephrectomy of the degree employed in the
remnant kidney model in the rat would be about one third of
that of the intact rat. Therefore, the metabolic clearance rate for
renin would remain greater than one half the control value.
Since the decrease in nephron number is of a greater degree
(typically, the ablative procedure employed leaves 10,000 to
15,000 functioning nephrons as compared to 60,000 in the sham
operated intact rats), the similar steady-state plasma renin
activities suggest a higher secretory rate per residual nephron.
That the renin content of residual nephrons is higher than that
of controls in this model seems even clearer since the total renal
content of renin is similar in the intact control and partially
ablated kidney, despite the lower number of nephrons in the
latter.
Inappropriate secretion of renin in the setting of human renal
disease was suggested by studies of Warren and Ferris, who
assessed the contribution of the RAS to the hypertension in
patients with end-stage renal disease. They noted a lack of
complete ream suppression in response to extracellular volume
expansion and hypothesized that inappropriate renin secretion
is a key pathophysiologic feature of renoprival hypertension
[591.
Alterations in the local renal renin-angiotensin system
As a classical endocrine system, circulating renin, derived
primarily from the kidney, cleaves angiotensinogen to the
decapeptide angiotensin I (Ang I) which is then converted to the
physiologically active heptapeptide angiotensin II (Ang II) by
the angiotensin converting enzyme (ACE) synthesized by vas-
cular endothelial and other cells. Evidence supports the pres-
ence of a local paracrine RAS in diverse tissues such as arterial
wall, kidney, heart, adrenal cortex, and central nervous system.
These local renin-angiotensin systems may be regulated inde-
pendently from their circulating counterparts. While the abso-
lute autonomy of the RAS within different tissues is uncertain,
the presence of a local renal RAS seems quite clear and its
presence has particular relevance to renal disease based on the
evidence presented above that the RAS may play a role in the
progression of renal disease.
Renin mRNA and renin activity were not increased in the
remnant kidney following subtotal nephrectomy when exam-
ined on a whole organ level [41, 60, 61]. In fact, with time a
decrease in renin mRNA was observed, perhaps reflecting
suppression secondary to volume expansion. Renal angioten-
sinogen mRNA was also lower in the remnant kidney compared
to sham operated controls, further ruling out activation of the
local renal RAS as an explanation for the dissociation between
response to Ang II inhibitors at a time when the systemic RAS
is not activated [60]. However, alterations in the distribution of
components of the RAS within the kidney could result in local
areas of activation of this system which would not be detectable
by the whole organ methodology employed in the above stud-
ies.
Within the kidney, internephron heterogeneity of renin syn-
thesis and storage occurs. Not all juxtaglomerular apparatuses
have renin staining cells and superficial nephrons generally
show greater renin stores than deeper ones [62, 63]. Variations
in the anatomical distribution of immunostainable remn have
been clearly demonstrated in experimental as well as in clinical
conditions. For example, during the course of normal kidney
maturation in the rat, there is migration of renin synthesis and
storage from proximal sites in the vascular tree to the juxtaglo-
merular apparatus [64]. Also, after administration of ACE
inhibitors renin containing cells reappear proximal to the jux-
taglomerular apparatus [63]. Distal migration of renin synthesis
and storage to the glomerular tuft has been noted in states of
mineralocorticoid deficiency and salt depletion [65]. With salt
depletion, mesangial cells likely constitute the renin producing
cell line within the glomerulus [66]. Furthermore, mesangial
cells can produce renin when cultivated in vitro [67].
Shifts in the anatomical distribution of renin occur in the
setting of chronic renal disease. Following subtotal nephrec-
tomy in the rat (the remnant kidney model of chronic renal
failure), renin accumulates within glomeruli, as demonstrated
by immunohistochemistry and enzymatic assay for glomerular
renin content [41]. That the remnant glomerulus becomes a site
of renin synthesis is supported by the finding of increased renin
mRNA in glomeruli from remnant kidneys compared to those
from control kidneys [41]. The effect of increased glomerular
renin in the remnant kidney is unknown, but could lead to
increased levels of Ang II which could contribute to the
hemodynamic alterations observed in this model, namely ele-
vation in glomerular capillary pressure and reduction of the
ultrafiltration coefficient [68].
In addition to the translocation of renin into the glomerular
tuft, a disproportionate amount of renin mRNA as well as an
increased renin content, determined by immunostaining and
enzymatic activity, arises in the tissue adjacent to the infarctive
scar following subtotal nephrectomy in the rat [60, 61]. Shifts of
renin into both the glomerulus and more proximal vasculature
occur in this region of renin activation [60]. In this regard,
glomeruli adjacent to an infarcted area show morphologic
evidence of ischemia without infarction [69]. These glomeruli
may be perfused by retrograde filling from contiguous non-
infarcted tissue [70]. This finding raises the possibility that such
hypoperfused glomeruli adjacent to the scar tissue are the
source of increased renin synthesis. Activation of the RAS in
the scar adjacent renal parenchyma after renal ablation by
infarction has been suggested on functional grounds by studies
of Meyer and Rennke, who compared the course of the renal
disease in rats with bilateral infarction of 40% of their renal
mass to uninephrectomized rats. The rats with limited bilateral
infarction exhibited more glomerular sclerosis, more severe
proteinuria, and increased systemic and glomerular pressures
compared to those that had undergone uninephrectomy [69].
Perhaps hypoperfusion of watershed zones at the borders of the
infarcts provokes renin production with both local and systemic
hemodynamic consequences, a sort of intrarenal Goldblatt
hypertension. Of great interest, Camillien and coworkers,
described increased immunostainable renin in ischemic lesions
at the edge of renal infarcts in clinical biopsy material providing
further clinical support for the possibility of increased renin
content in regions of ischemia [71]. In addition, these investi-
gators noted that immunostainable ream was diminished in the
kidney parenchyma distant from the ischemic lesion, perhaps
due to suppression by high levels of intrarenal Ang II produced
by the ischemic glomeruli [71]. This local elevation of renin
Rosenberg et a!: The renin-angiotensin system 407
could exert very localized effects at the margins of the scar, but
could also influence more distant nephrons within the same
kidney, as renin and Ang II can diffuse through the renal
interstitium [72].
These patterns of intrarenal renin redistribution may underlie
increased renal activity of the RAS in the presence of the low to
normal PRA usually observed in chronic renal failure. Further-
more, this variability in the intrarenal distribution of renin
synthesis and storage may play a role in the well recognized, yet
poorly understood phenomenon of internephron heterogeneity
of renal injury [73]. An increased production of renin and hence
of Ang II within certain nephrons and their vasculature, per-
haps through microscopic scarring and ischemic lesions in
many types of diffuse chronic renal injury, could participate in
local injury through both hemodynamic and non-hemodynamic
actions of Ang II.
Human renal biopsies in several pathological conditions have
also shown variations in the distribution of vascular immuno-
staining of renin [74—82]. The patterns of staining that can be
observed vary widely, both in intensity as well as in location. In
renal artery stenosis, there is an increase in renin-containing
cells in the juxtaglomerular apparatuses as well as in the
proximal vascular tree, with extension as far as the interlobular
arteries [78]. Similarly, immunostainable renin located in arte-
rioles at a distance from glomeruli was identified in renal
biopsies of patients with end-stage renal disease and dialysis
resistant hypertension [74]. In cases of segmental renal hypo-
plasia, the scarred and/or hypoplastic segments show increased
renin staining, while the preserved renal tissue displays normal
or reduced renin immunostaining [81]. A loss of the normal
gradient of renin-containing cells from greatest in superficial to
least in deep cortex can be observed in classical polyartentis
nodosa [80]. As well, proximal extension of renin secreting cells
into the vascular tree has been described in this disease, a
pattern similar to that seen in renal artery stenosis [78]. Graham
and Lindop suggest that the focal ischemia present in these
conditions may constitute the stimulus for renin production
[80].
An abnormal pattern of renin-containing cells within the
kidney is also present in adult polycystic kidney disease [76,
77]. In those areas with histologically normal kidney tissue,
renin-containing cells were located in the usual location in the
juxtaglomerular apparatuses at the vascular pole. In scarred
tissue, defined as fibrosed renal parenchyma with some identi-
fiable residual renal tissue, renin-containing cells were present
in juxtaglomerular apparatuses, in arterioles, and also in more
proximal arterial walls. Fibrous tissue without any recognizable
renal structures encased renin containing cells located within
small arterioles and adjacent to cyst walls. Serial sections have
demonstrated that these renin-positive cells were not connected
with the renal arterial tree [76]. Tones et al have also demon-
strated renin immunostaining in epithelial cells lining dilated
tubules and cysts as well as in cultured cells derived from cyst
walls [77]. Renin mRNA was present in the cultured cells and
immunoreactive and enzymatic renin was present in cyst fluid
suggesting synthesis and secretion of renin by the cyst epithe-
lium. Such activation of the RAS in cysts could contribute to
cyst growth and/or hypertension.
Peh and Lindop recently reported the morphological distri-
bution of renin-containing cells in renal biopsies diagnosed as
chronic pyelonephritis. Renin-containing cells were present in
juxtaglomerular apparatuses of surviving nephrons, proximal to
the glomerulus up to interlobular arteries, and in some cases
renin was identified within the glomerular tufts [79]. Renin
containing cells have also been occasionally identified within
the glomerular mesangium in cases of renal artery stenosis [78],
and in pseudo-Bartter's syndrome secondary to cathartic and/or
diuretic abuse [82]. Immunostainable renin-containing cells
often appear at the vascular pole of even fibrosed and obsoles-
cent glomeruli [75].
Alterations in the physiologic control of the renin-angiotensin
system
Under physiologic and pathophysiologic conditions, multiple
mechanisms participate in regulating the components of the
RAS, including synthesis and secretion of renin. The interac-
tion of these mechanisms significantly complicates the assess-
ment of the individual role of a particular mechanism in renal
disease. The increased perfusion pressure and increased distal
sodium delivery present in the remnant kidney model would
predict a suppression of renin secretion and could account for
the low PRA sometimes noted in this model. However, several
other locally generated signals act together with the mechani-
cal, neural, and chemical mediators to regulate the rate of renin
release. Prostaglandins are among the most extensively studied
of these paracrine regulators, and in the remnant kidney model,
renal production of prostaglandins rises [83, 84]. Furthermore,
prostaglandin species, mainly POE2 and PGI2 serve as renin
secretagogues [85, 86]. Thus, these substances would be ex-
pected to stimulate renin secretion and tend to offset the
inhibitory actions of hypertension and augmented distal tubular
salt concentrations in the diseased kidney. The relative contri-
butions of these stimulatory (prostaglandins) and inhibitory
(baroreceptor and macula densa) effects are uncertain but their
aggregate actions generally yield normal to low levels of PRA in
the remnant kidney model. The activity of adrenergically me-
diated renin release is unknown in this model or in clinical
chronic renal disease. Moreover, a great diversity of circulating
hormones and other local factors such as vasopressin and atrial
natriuretic peptide, neuropeptide Y, vasoactive intestinal
polypeptide, dopamine, platelet activating factor, endothelin
and adenosine among others, can modify renin release [40].
While many of these factors may be altered in chronic renal
disease, their degrees of participation and interaction in the
pathophysiological control of renin synthesis and secretion in
this state remains to be defined.
Other actions of the renin-angiotensin system
Angiotensin II has a number of non-hemodynamic actions
which may take on pathophysiologic significance when they
occur in the setting of chronic renal disease (Table 1). Renal
growth, particularly of the glomerulus, has been implicated as a
factor associated with renal injury and indeed glomerular en-
largement may predispose to injury [87]. Ang II promotes
growth in a number of cells and tissues including vascular
smooth muscle, adrenal cortex, heart and kidney [88—91]. In the
kidney the clearest growth effects of Ang II are on proximal
tubular cells wherein Ang II induces hypertrophy and potenti-
ates the mitogenic response of these cells to epidermal growth
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Table 1. Effects of the renin-angiotensin system which could
contribute to progression of renal disease
• Hypertension
—systemic
—glomerular
• Renal growth
• Ammonia production
—growth
—complement activation
• Mesangial trafficking of macromolecules
• Increased sodium reabsorption
factor [91, 92]. In mesangial cells, Ang II increases 3H-thyrni-
dine incorporation, induces hypertrophy, and stimulates colla-
gen and actin synthesis [92—951. In vivo, intrarenal infusion of
Ang II increases the expression of several early growth re-
sponse genes, an effect associated with cellular growth in other
tissues [96]. The induction of these genes by Ang II may be
secondary to hemodynamic effects since vasoconstriction pro-
duced by norepinephrine resulted in a similar increase in early
growth response gene mRNA [96].
Besides direct growth effects of Ang II, another mechanism
by which Ang II could stimulate renal growth is through its
ability to stimulate ammoniagenesis in renal tubular cells [97].
Ammonia stimulates renal tubular hypertrophy [98]. Also,
increased concentrations of ammonia in the renal cortex which
occur in the setting of reduced renal mass can induce tubulointer-
stitial disease by interacting with the complement component
C3 resulting in activation of the complement cascade [99]. Ang
II also affects mesangial trafficking leading to increased uptake
of macromolecules in the mesangium, which may predispose to
eventual glomerular sclerosis [100]. Finally, Ang II increases
renal tubular reabsorption of sodium which would augment
oxygen consumption by the kidney [101]. Oxidant stress on
surviving nephrons may exacerbate renal injury [102]. Thus,
Ang II could contribute to the progression of renal disease
through both its hemodynamic and non-hemodynamic actions.
Summary
Despite normal to suppressed levels of renin activity in
chronic renal disease, multiple lines of evidence suggest a role
for the RAS, especially its intrarenal expression, in several
critical aspects of this condition. Alterations in the distribution
and control of components of the renal RAS could account for
localized areas of activation of this system. Renal scarring may
be particularly important as a major stimulus to renin synthesis
in the diseased kidney. While both intrarenal and systemic
hypertension may depend in part upon actions of the RAS,
other non-hemodynamic actions of the RAS may also contrib-
ute to the adaptation of residual nephrons as well as their
progressive injury.
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